Beclabuvir (also known by the research name BMS-791325; abbreviated BCV) is an antiviral drug for the treatment of hepatitis C virus (HCV) infection that has been studied in clinical trials. In February 2017, Bristol-Myers Squibb began sponsoring a post-marketing trial of beclabuvir, in combination with asunaprevir and daclatasvir, to study the combination's safety profile with regard to liver function.[1] From February 2014 to November 2016, a phase II clinical trial was conducted on the combination of asunaprevir/daclatasvir/beclabuvir (beclabuvir is referred to as BMS-791325 in the trial) on patients infected with both HIV and HCV.[2] Furthermore, a recent meta-analysis of six published six clinical trials showed high response rates in HCV genotype 1-infected patients treated with daclatasvir, asunaprevir, and beclabuvir irrespective of ribavirin use, prior interferon-based therapy, or restriction on noncirrhotic patients, IL28B genotype, or baseline resistance-associated variants[3]
Beclabuvir acts as a NS5B (RNA polymerase) inhibitor.[4]
Referencesedit
^Clinical trial number NCT03071133 for "Asunaprevir/Daclatasvir/Beclabuvir Fixed-Dose Combination Safety Surveillance in Japanese Patients With Chronic Hepatitis C (HCV) or Japanese Patients With Compensated Cirrhosis" at ClinicalTrials.gov
^Clinical trial number NCT02124044 for "Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV" at ClinicalTrials.gov
^Ahmed AM, Doheim MF, Mattar OM, Sherif NA, Truong DH, Hoa PT, et al. (May 2018). "Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis". Journal of Medical Virology. 90 (5): 907–918. doi:10.1002/jmv.24947. PMID 28892235. S2CID 3829214.
^Tatum H, Thuluvath PJ, Lawitz E, Martorell C, DeMicco M, Cohen S, et al. (August 2015). "A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1". Journal of Viral Hepatitis. 22 (8): 658–64. doi:10.1111/jvh.12372. PMID 25496007.
beclabuvir, also, known, research, name, 791325, abbreviated, antiviral, drug, treatment, hepatitis, virus, infection, that, been, studied, clinical, trials, february, 2017, bristol, myers, squibb, began, sponsoring, post, marketing, trial, beclabuvir, combina. Beclabuvir also known by the research name BMS 791325 abbreviated BCV is an antiviral drug for the treatment of hepatitis C virus HCV infection that has been studied in clinical trials In February 2017 Bristol Myers Squibb began sponsoring a post marketing trial of beclabuvir in combination with asunaprevir and daclatasvir to study the combination s safety profile with regard to liver function 1 From February 2014 to November 2016 a phase II clinical trial was conducted on the combination of asunaprevir daclatasvir beclabuvir beclabuvir is referred to as BMS 791325 in the trial on patients infected with both HIV and HCV 2 Furthermore a recent meta analysis of six published six clinical trials showed high response rates in HCV genotype 1 infected patients treated with daclatasvir asunaprevir and beclabuvir irrespective of ribavirin use prior interferon based therapy or restriction on noncirrhotic patients IL28B genotype or baseline resistance associated variants 3 BeclabuvirClinical dataOther namesBMS 791325Legal statusLegal statusUS Investigational New DrugIdentifiersIUPAC name 1aR 12bS 8 Cyclohexyl N dimethylsulfamoyl 11 methoxy 1a 1R 5S 3 methyl 3 8 diazabicyclo 3 2 1 oct 8 yl carbonyl 1 1a 2 12b tetrahydrocyclopropa d indolo 2 1 a 2 benzazepine 5 carboxamideCAS Number958002 33 0PubChem CID56934415ChemSpider27289076UNIIMYW1X5CO9SKEGGD10610 YChemical and physical dataFormulaC 36H 45N 5O 5SMolar mass659 85 g mol 13D model JSmol Interactive imageSMILES CN1C C H 2CC C H C1 N2C O C 34C C H 3c5cc ccc5 c6c c7ccc cc7n6C4 C O NS O O N C C C8CCCCC8 OCInChI InChI 1S C36H45N5O5S c1 38 2 47 44 45 37 34 42 23 10 14 28 31 16 23 40 21 36 35 43 41 24 11 12 25 41 20 39 3 19 24 18 30 36 29 17 26 46 4 13 15 27 29 33 40 32 28 22 8 6 5 7 9 22 h10 13 17 22 24 25 30H 5 9 11 12 18 21H2 1 4H3 H 37 42 t24 25 30 36 m0 s1Key ZTTKEBYSXUCBSE QDFUAKMASA NPharmacology editBeclabuvir acts as a NS5B RNA polymerase inhibitor 4 References edit Clinical trial number NCT03071133 for Asunaprevir Daclatasvir Beclabuvir Fixed Dose Combination Safety Surveillance in Japanese Patients With Chronic Hepatitis C HCV or Japanese Patients With Compensated Cirrhosis at ClinicalTrials gov Clinical trial number NCT02124044 for Safety Tolerability and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV HCV at ClinicalTrials gov Ahmed AM Doheim MF Mattar OM Sherif NA Truong DH Hoa PT et al May 2018 Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection A systematic review and meta analysis Journal of Medical Virology 90 5 907 918 doi 10 1002 jmv 24947 PMID 28892235 S2CID 3829214 Tatum H Thuluvath PJ Lawitz E Martorell C DeMicco M Cohen S et al August 2015 A randomized placebo controlled study of the NS5B inhibitor beclabuvir with peginterferon ribavirin for HCV genotype 1 Journal of Viral Hepatitis 22 8 658 64 doi 10 1111 jvh 12372 PMID 25496007 nbsp This antiinfective drug article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Beclabuvir amp oldid 1187850094, wikipedia, wiki, book, books, library,
